Dr. Joseph J. Vadakara
Claim this profileGeisinger Medical Center
Studies Leukemia
Studies Lymphoma
20 reported clinical trials
60 drugs studied
About Joseph J. Vadakara
Education:
- Obtained MD from Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, in 1987.
- Completed Residency in Internal Medicine at Geisinger Medical Center, Danville, PA (1987-1990).
- Undertook Fellowship in Cardiovascular Disease at Geisinger Medical Center, Danville, PA (1990-1993).
Experience:
- Currently serves as a Cardiologist and Professor of Medicine at Geisinger Medical Center.
Area of expertise
1Leukemia
BCR-ABL positive
Stage I
Stage II
2Lymphoma
CD20 positive
13q positive
13q negative
Affiliated Hospitals
Clinical Trials Joseph J. Vadakara is currently running
Inotuzumab Ozogamicin + Chemotherapy
for Leukemia and Lymphoma
This trial tests a new treatment combining inotuzumab ozogamicin with chemotherapy for patients with certain types of blood cancer. The new drug targets cancer cells directly and delivers a toxin to kill them. This approach aims to improve the effectiveness of treatment compared to standard chemotherapy alone. Inotuzumab ozogamicin has shown superior efficacy compared to conventional chemotherapy in patients with specific types of blood cancer.
Recruiting3 awards Phase 2
Pembrolizumab + TKI
for Chronic Myeloid Leukemia
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.
Recruiting1 award Phase 2
More about Joseph J. Vadakara
Clinical Trial Related5 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Joseph J. Vadakara has experience with
- Dasatinib
- Pembrolizumab
- Obinutuzumab
- Lenalidomide
- Cytarabine
- Dexamethasone
Breakdown of trials Joseph J. Vadakara has run
Leukemia
Lymphoma
Skin Cancer
Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Joseph J. Vadakara specialize in?
Joseph J. Vadakara focuses on Leukemia and Lymphoma. In particular, much of their work with Leukemia has involved BCR-ABL positive patients, or patients who are Stage I.
Is Joseph J. Vadakara currently recruiting for clinical trials?
Yes, Joseph J. Vadakara is currently recruiting for 9 clinical trials in Danville Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Joseph J. Vadakara has studied deeply?
Yes, Joseph J. Vadakara has studied treatments such as Dasatinib, Pembrolizumab, Obinutuzumab.
What is the best way to schedule an appointment with Joseph J. Vadakara?
Apply for one of the trials that Joseph J. Vadakara is conducting.
What is the office address of Joseph J. Vadakara?
The office of Joseph J. Vadakara is located at: Geisinger Medical Center, Danville, Pennsylvania 17822 United States. This is the address for their practice at the Geisinger Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.